RecruitingNot ApplicableNCT06463938

A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH

A Clinical Study to Evaluate the Effectiveness of Casein Phosphopeptide, Amorphous Calcium Phosphate Paste (CPP-ACP) Used Alone or in Combination With Lasotronix (Diode Laser) to Treat Dentin Hypersensitivity


Sponsor

Dow University of Health Sciences

Enrollment

120 participants

Start Date

May 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).


Eligibility

Min Age: 25 YearsMax Age: 65 Years

Inclusion Criteria2

  • Patients of either gender, with ages between 25-65 years
  • should have at least more than one hypersensitive and vital tooth without any carious lesion or defective restoration

Exclusion Criteria5

  • History of desensitizing therapy on the affected tooth/teeth in last six months (use of desensitizing toothpaste)
  • use of antibiotics /analgesic/anti-inflammatory drugs
  • history of smoking
  • pregnancy
  • those who are not willing to participate or give follow-ups

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERActive comparator

CPP-ACP paste will be applied on exposed area

DEVICEExperimental group

Lasotronix will be applied following its protocol

COMBINATION_PRODUCTCombination of laser and paste

This group will receive the combination of above two treatments

BEHAVIORALControl group

this will be a control group


Locations(1)

Dr Sanam Faheem

Karachi, Sindh, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06463938


Related Trials